Background: BRCA1 Associated RING Domain gene 1 (BARD1) interacts with the N terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, BARD1 shares homology with the 2 most conserved regions of BRCA1: the N terminal RING motif and the C terminal BRCT domain. The RING motif is a cysteine rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. The BARD1 protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. BARD1 may be the target of oncogenic mutations in breast or ovarian cancer. BARD1 also plays a role in mediating apoptotic stress and p53 dependent.
Description: Rabbit polyclonal to BARD1
Immunogen: KLH conjugated synthetic peptide derived from BARD1
Specificity: ·Reacts with Human, Mouse, Pig, Dog and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 86 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry: 1/100;
·Immunofluorescence: 1/50-200;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
